<DOC>
	<DOCNO>NCT01864096</DOCNO>
	<brief_summary>This study aim see metformin delay time progression men low risk prostate cancer compare placebo .</brief_summary>
	<brief_title>The Metformin Active Surveillance Trial ( MAST ) Study</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Must male &gt; 18 &lt; 80 year age 2 . Have biopsy proven , lowrisk , localized prostate cancer choose expectant management primary treatment ≤ 1year . [ For purpose assess subject eligibility diagnostic biopsy must include least 10 core , &lt; 3 core positive &lt; 50 % one core positive ) must obtain within 6 month screen ] . Initial diagnosis T1a/T1b obtain TURP allow 3 . Gleason score ≤ 6 [ Gleason pattern 4 must present biopsy ( initial entry ) ] 4 . Clinical stage T1cT2a 5 . Serum PSA ≤10 ng/mL ( prior biopsy ) 6 . Life expectancy great 5 year , judge treat clinician/urologist 7 . Able swallow retain oral medication 8 . Hemoglobin A1c &lt; 6.5 % 9 . Able willing participate full 3 year study 10 . Able understand instruction relate study procedures 11 . Able read write ( health outcome questionnaire selfadministered ) , understand instruction relate study procedure give write informed consent 1 . Subject ever treat prostate cancer follow : Radiotherapy ( external beam brachytherapy ) Chemotherapy Hormonal therapy ( e.g. , megestrol , medoxyprogesterone , cyproterone ) Oral glucocorticoid GnRH analogue ( e.g. , leuprolide , goserelin , degarelix ) 2 . Current and/or previous use follow medication : Use 5αreductase inhibitor ( eg . Finasteride , Dutasteride ) within past 6 month screen Drugs antiandrogenic property ( e.g. , flutamide , bicalutamide , ketoconazole , progestational agent ) within 6 month prior screen 3 . Previous current diagnosis type 1 type 2 diabetes 4 . Exposure metformin within 12 month screen 5 . Planned concurrent use metformin hydrochloride , sulfonylurea , thiazolidinediones , insulin reason 6 . Known hypersensitivity intolerance metformin hydrochloride 7 . Any condition associate increase risk metformin hydrochlorideassociated lactic acidosis ( e.g . congestive heart failure define NYHA class III IV , history type acidosis , habitual intake ≥ 4 alcoholic beverage per day ) 8 . Subject prior prostatic surgery include TUNA , TURP , TUIP , laser treatment , thermotherapy , balloon dilatation , prosthesis , ultrasound ablation within 3 month screen 9 . Participation investigational market drug trial within 30 day prior screen anytime study period . This include interventional exercise trial 10 . Any unstable serious coexist medical condition ( ) include , limited , myocardial infarction , coronary bypass surgery , unstable angina , cardiac arrhythmia , clinically evident congestive heart failure , cerebrovascular accident within 6 month prior Screening visit 11 . Abnormal liver function test : Total bilirubin &gt; 1.8 X institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) &gt; 1.8 X institutional ULN Alanine aminotransferase ( ALT ) &gt; 1.8 X institutional ULN Alkaline phosphatase ( ALP ) &gt; 1.8 X institutional ULN 12 . Serum creatinine &gt; 1.8 X ULN 13 . History malignancy , exception adequately treat nonmelanoma skin cancer , stage I melanoma , NMIBC solid tumor curatively treat evidence disease least 5 year 14 . History current evidence substance abuse , define DSMIV , within 12 month screen 15 . History illness ( include psychiatric ) , opinion investigator , might confound result study pose additional risk subject 16 . No concurrent metformin hydrochloride , sulfonylurea , thiazolidinediones , insulin reason</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>localize</keyword>
	<keyword>prostate</keyword>
	<keyword>cancer</keyword>
	<keyword>metformin</keyword>
	<keyword>active surveillance</keyword>
</DOC>